Still Stressed Out but Doing Fine
2002; Lippincott Williams & Wilkins; Volume: 105; Issue: 1 Linguagem: Inglês
10.1161/circ.105.1.8
ISSN1524-4539
AutoresMotoaki Sano, Michael Schneider,
Tópico(s)Cardiovascular Effects of Exercise
ResumoHomeCirculationVol. 105, No. 1Still Stressed Out but Doing Fine Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBStill Stressed Out but Doing FineNormalization of Wall Stress Is Superfluous to Maintaining Cardiac Function in Chronic Pressure Overload Motoaki Sano, MD and Michael D. Schneider, MD Motoaki SanoMotoaki Sano From the Center for Cardiovascular Development and Department of Medicine (M.S.), and the Departments of Molecular and Cellular Biology and Molecular Physiology and Biophysics (M.D.S.), Baylor College of Medicine, Houston, Tex. and Michael D. SchneiderMichael D. Schneider From the Center for Cardiovascular Development and Department of Medicine (M.S.), and the Departments of Molecular and Cellular Biology and Molecular Physiology and Biophysics (M.D.S.), Baylor College of Medicine, Houston, Tex. Originally published1 Jan 2002https://doi.org/10.1161/circ.105.1.8Circulation. 2002;105:8–10Classically, myocardial hypertrophy is viewed as a long-term adaptive response of cardiac muscle to altered mechanical loading conditions, in which increasing wall thickness serves as the means to restore wall stress to normal, obeisant to the law of Laplace.1 The concept of local biomechanical stress as an instigator for this has been made clear through animal models, studies of cardiac muscle cells stretched in tissue culture, and long-standing clinical wisdom as with obstruction to right versus left ventricular outflow, respectively. Perhaps the most nebulous aspect of load-induced hypertrophy remains the exact identity of the initial mechanoreceptors—mechanical sensor(s) that become activated by a hemodynamic burden — although molecules that physically connect the cytoskeleton to the cell's extracellular environment are among the prime candidates, including integrins and focal adhesion kinases. Much more is known of the intracellular signaling pathways that lie biochemically and genetically downstream from these initiating events, such as the secretion of preformed growth factors and cytokines, acting in autocrine or paracrine fashion, as well as the upregulation of the production of such proteins locally within the heart.1–3 In the context of whole-animal and clinical physiology, systemic effects, including an increase in catecholamines, also come into play. These multiple signals (ligand-dependent and overlaid on those induced by load itself) are transmitted to the cell nucleus via an intricate web of interlinked protein kinases, phospholipid kinases, and protein phosphatases.1–3 Beyond just increased mass, the specific long-term transcriptional responses to load entail a myriad of quantitative and qualitative changes in cardiac gene expression that are reminiscent of fetal cardiac myocytes, and are now understood to encompass contractile proteins, ion pumps and channels, secreted proteins, signaling proteins, enzymes involved in cardiac energetics, components of the extracellular matrix, and even regulators of cell survival.1–3 The list of such changes in cardiac hypertrophy is now growing rapidly as the fruit of high-throughput gene chip technology and other methods of expression profiling.See p 85With greater insight into the particulars of the hypertrophic phenotype has come the recognition that changes once viewed simplistically as homeostatic (linked by their shared teleological value) demand a more nuanced interpretation in which beneficial and adverse responses are comingled. Ventricular hypertrophy is demonstrably a risk factor for cardiovascular mortality in humans,4 which has spurred efforts to antagonize ligands, receptors, cytoplasmic transducers, and even nuclear mediators that act in the hypertrophic cascade.1–3 However, the nominally adaptive value of hypertrophy in response to load has remained a point of controversy in understanding progression to heart failure, and with the advent of left ventricular assist devices and other recent therapies for reverse remodeling, has become even more important than in the past.In the present issue of Circulation, Esposito et al5 add striking and important new evidence on this matter: Using genetically engineered mice that have markedly blunted growth responses to pressure overload, they demonstrate that cardiac function was well maintained after loading (using a partial aortic constriction), despite the failure to correct wall stress. Indeed, function was even better maintained than in wild-type mice where hypertrophy ensued. Hence, this investigation casts doubt on the assumption that load-induced hypertrophy has adaptive value.Two specific, intriguing genetic models were used to explore this view. Angiotensin II and endothelin are, clinically, among the most convincingly important hypertrophic agonists, with direct effects on cardiac muscle in addition to their systemic ones.1–3 Their receptors signal obligatorily through the GTP-binding protein Gαq, as also do the receptors for α1-adrenergic agonists. Expressing a carboxyl-terminal fragment of this protein in the hearts of transgenic mice interferes with the endogenous protein's function (as a dominant-inhibitory peptide, to use the jargon of the trade) and blocks hypertrophy induced by load.6 As a second and independent test of the hypothesis, the authors used mice in which both alleles for dopamine β-hydroxylase have been disrupted: such mice lack the ability to make norepinephrine or epinephrine and likewise have attenuated growth responses to load.7 The authors' experimental strategy was technically daunting, including pressure-volume and stress-strain analysis in mice.Measured in this fashion one week after banding, end-systolic wall stress was found to be corrected to control levels in wild-type mice but not in mice expressing the Gαq inhibitor, where wall stress was roughly 2-fold greater. Nonetheless, wild-type mice ultimately fared worse in response to long-term load, as shown by progressive LV dilatation and dysfunction on serial echocardiography. In short, cardiac function was preserved by the genetic alteration, despite high wall stress, whereas wild-type mice deteriorated progressively, despite the early correction of wall stress by means of hypertrophic growth. Hence, from these paired observations, the article's "take-home" message is that normalizing wall stress is dispensable to preserve cardiac function in the face of a long-term hemodynamic burden. Similarly, wild-type mice fared worse than those lacking dopamine β-hydroxylase, with the caveat that wall stress was not measured in this latter case.Apart from their suggestive pathophysiological importance, the long-term findings reported in this manuscript also add credibly to the evolving notion of Gαq as a therapeutic target in heart failure. Whether Gαq itself is more workable or advantageous a target than its effectors is not yet clear, of course, and such answers often come empirically, rather than from conceptual principles. The 2 mouse models studied by Esposito et al have biochemical effects that invite speculation, but also counter-speculation. A prominent effect of both genetic interventions is a block to load-induced activation of phosphoinositide 3-kinase (PI3-K), a family of lipid kinases that catalyze phosphorylation at the 3-position of the inositol ring of phosphoinositides. Downstream signaling targets that are activated directly or indirectly by PI3-K lipid products are numerous and ramified: Akt (protein kinase B), protein kinase Cε, phospholipase Cγ, the GTP-binding protein Rac, and p70 S6 kinase among them. Notably, PI3-K and several of these targets are known to cause cardiac hypertrophy at least in mice.8–10 Because a lack of PI3-K activation after aortic banding in the genetically altered mice was associated with preserved ventricular function in the present study, the authors suggest as a logical and conservatively stated inference: that inhibition of PI3-K might prove beneficial in preventing the transition from cardiac hypertrophy to heart failure.5However, hypertrophy spans the good, the bad, and the global. Notwithstanding hypertrophy as a clinical risk factor, certain specific changes might be likelier than mass per se to predicate the transition from a compensated state to a decompensated one. A priori alterations that impair myocyte contractile function seem more germane, defective β-adrenergic signaling and calcium homeostasis among them, especially where molecular correction of the defect already has proven utility.11,12 Other responses, including signals for cell survival itself, may be essential after increased wall stress.13In further support of this concept, several genetic models now exist of hypertrophy that is well tolerated or even beneficial. The mitogen-activated protein kinase (MAPK) superfamily culminates in 3 subfamilies of terminal effector kinases: extracellular signal–regulated protein kinase (ERK), c-jun N-terminal kinase (JNK), and p38 MAPKs. Specific activation of ERK by a kinase that lies upstream caused concentric hypertrophy without decompensation accompanied by marked resistance to apoptotic cell death.14 A very similar phenotype can be elicited in myocardium by a very different mechanism, namely preventing the normal downregulation of telomerase reverse transcriptase after birth15; this RNA-dependent DNA polymerase has an important role not only in senescence but also in DNA repair. By contrast, a catastrophic cardiomyopathy is evoked by selective activators of either p38 or JNK,14,16,17 thus incriminating these kinases more so than ERK as targets for drug development in heart failure. Mass, in fact, increases far less in these models than where ERK activation predominates. Likewise, the PI3-K/Akt pathway can promote cardiac myocyte growth that is perhaps more physiological and is associated with cardioprotection in cell culture18 and in mice.8,19For this reason, although the authors' argument that PI3-K contributes to β-adrenergic receptor desensitization20 and that improvements might result is conceptually sound, on such grounds, from its inhibition, one must append a cautionary note that PI3-K has multiple other effects in the heart, some of which, at least experimentally, may oppose the transition to heart failure. From the same perspective, the fact that normalization of wall stress is superfluous in the present study may be contingent on the absence of specific adverse responses to load, which have been disrupted concomitantly. Answering the question of who is "good" and who is "bad" in heart failure has never seemed so timely as in the present era of new molecular phenotypes and the emerging potential for more rational therapies.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Michael D. Schneider, MD, Center for Cardiovascular Development, Baylor College of Medicine, One Baylor Plaza, Room 506D, Houston, TX. E-mail [email protected] References 1 Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997; 59: 551–571.CrossrefMedlineGoogle Scholar2 MacLellan WR, Schneider MD. Genetic dissection of cardiac growth control pathways. Annu Rev Physiol. 2000; 62: 289–320.CrossrefMedlineGoogle Scholar3 Molkentin JD, Dorn IGII. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 2001; 63: 391–426.CrossrefMedlineGoogle Scholar4 Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001; 104: 1615–1621.CrossrefMedlineGoogle Scholar5 Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 2002: 105: 85–92.CrossrefMedlineGoogle Scholar6 Akhter SA, Luttrell LM, Rockman HA, et al. Targeting the receptor-G(q) interface to inhibit in vivo pressure overload myocardial hypertrophy. Science. 1998; 280: 574–577.CrossrefMedlineGoogle Scholar7 Rapacciuolo A, Esposito G, Caron K, et al. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J Am Coll Cardiol. 2001; 38: 876–882.CrossrefMedlineGoogle Scholar8 Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000; 19: 2537–2548.CrossrefMedlineGoogle Scholar9 Sussman MA, Welch S, Walker A, et al. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest. 2000; 105: 875–886.CrossrefMedlineGoogle Scholar10 Chen L, Hahn H, Wu G, et al. Opposing cardioprotective actions and parallel hypertrophic effects of δPKC and εPKC. Proc Natl Acad Sci U S A. 2001; 98: 11114–11119.CrossrefMedlineGoogle Scholar11 Harding VB, Jones LR, Lefkowitz RJ, et al. Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci U S A. 2001; 98: 5809–5814.CrossrefMedlineGoogle Scholar12 Minamisawa S, Hoshijima M, Chu G, et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 1999; 99: 313–322.CrossrefMedlineGoogle Scholar13 Hirota H, Chen J, Betz UA, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999; 97: 189–198.CrossrefMedlineGoogle Scholar14 Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 2000; 19: 6341–6350.CrossrefMedlineGoogle Scholar15 Oh H, Taffet GE, Youker KA, et al. Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Proc Natl Acad Sci U S A. 2001; 98: 10308–10313.CrossrefMedlineGoogle Scholar16 Zhang D, Gaussin V, Taffet GE, et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med. 2000; 6: 556–563.CrossrefMedlineGoogle Scholar17 Liao P, Georgakopoulos D, Kovacs A, et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A. 2001; 98: 12283–12288.CrossrefMedlineGoogle Scholar18 Oh H, Fujio Y, Kunisada K, et al. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. J Biol Chem. 1998; 273: 9703–9710.CrossrefMedlineGoogle Scholar19 Shioi T, Kang PM, Obata T, et al. Regulation of growth and survival by Akt/PKB in mice. Circulation. 2000; 102: II-159.Abstract.Google Scholar20 Naga Prasad SV, Barak LS, Rapacciuolo A, et al. Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by β-adrenergic receptor kinase 1: a role in receptor sequestration. J Biol Chem. 2001; 276: 18953–18959.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Kulikowski E, Rakai B and Wong N (2020) Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases, Medicinal Research Reviews, 10.1002/med.21730, 41:1, (223-245), Online publication date: 1-Jan-2021. Ding J, Chen Y, Chen Y, Mou Y, Sun X, Dai D, Zhao C, Yang J, Hu S and Guo X (2020) Overexpression of FNTB and the activation of Ras induce hypertrophy and promote apoptosis and autophagic cell death in cardiomyocytes, Journal of Cellular and Molecular Medicine, 10.1111/jcmm.15533, 24:16, (8998-9011), Online publication date: 1-Aug-2020. Coleman A and Brown S (2020) Hypertension and the Heart and Vasculature Hypertension in the Dog and Cat, 10.1007/978-3-030-33020-0_8, (187-215), . Skaria T, Mitchell K, Vogel O, Wälchli T, Gassmann M and Vogel J (2019) Blood Pressure Normalization–Independent Cardioprotective Effects of Endogenous, Physical Activity–Induced αCGRP (α Calcitonin Gene-Related Peptide) in Chronically Hypertensive Mice, Circulation Research, 125:12, (1124-1140), Online publication date: 6-Dec-2019. Sano M, Kamitsuji S, Kamatani N, Tabara Y, Kawaguchi T, Matsuda F, Yamagishi H, Fukuda K and Minamino T (2016) Genome-Wide Association Study of Absolute QRS Voltage Identifies Common Variants of TBX3 as Genetic Determinants of Left Ventricular Mass in a Healthy Japanese Population, PLOS ONE, 10.1371/journal.pone.0155550, 11:5, (e0155550) Abeyrathna P and Su Y (2015) The critical role of Akt in cardiovascular function, Vascular Pharmacology, 10.1016/j.vph.2015.05.008, 74, (38-48), Online publication date: 1-Nov-2015. de Marvao A, Dawes T, Shi W, Durighel G, Rueckert D, Cook S and O'Regan D (2015) Precursors of Hypertensive Heart Phenotype Develop in Healthy Adults, JACC: Cardiovascular Imaging, 10.1016/j.jcmg.2015.08.007, 8:11, (1260-1269), Online publication date: 1-Nov-2015. Yang J, Mou Y, Wu T, Ye Y, Jiang J, Zhao C, Zhu H, Du C, Zhou L and Hu S (2012) Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice, Cardiovascular Research, 10.1093/cvr/cvs347, 97:3, (490-499), Online publication date: 1-Mar-2013., Online publication date: 1-Mar-2013. Melenovsky V (2013) Cardiac Adaptation to Volume Overload Cardiac Adaptations, 10.1007/978-1-4614-5203-4_9, (167-199), . Das M and Das D (2012) Caveolae, caveolin, and cavins: Potential targets for the treatment of cardiac disease, Annals of Medicine, 10.3109/07853890.2011.577445, 44:6, (530-541), Online publication date: 1-Sep-2012. Phan T, Shivu G, Abozguia K, Sanderson J and Frenneaux M (2012) The pathophysiology of heart failure with preserved ejection fraction: From molecular mechanisms to exercise haemodynamics, International Journal of Cardiology, 10.1016/j.ijcard.2011.06.113, 158:3, (337-343), Online publication date: 1-Jul-2012. Xie J, Lu W, Gu R, Dai Q, Zong B, Ling L, Xu B and Qin G (2011) The Impairment of ILK Related Angiogenesis Involved in Cardiac Maladaptation after Infarction, PLoS ONE, 10.1371/journal.pone.0024115, 6:9, (e24115) Lam C, Grewal J, Borlaug B, Ommen S, Kane G, McCully R and Pellikka P (2010) Size, Shape, and Stamina, Hypertension, 55:5, (1143-1149), Online publication date: 1-May-2010. Choi Y, Cowan D, Moran A, Colan S, Stamm C, Takeuchi K, Friehs I, del Nido P and McGowan F (2009) Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium, The Journal of Thoracic and Cardiovascular Surgery, 10.1016/j.jtcvs.2008.12.020, 137:6, (1356-1362.e3), Online publication date: 1-Jun-2009. Dorn II G and Diwan A (2008) The rationale for cardiomyocyte resuscitation in myocardial salvage, Journal of Molecular Medicine, 10.1007/s00109-008-0362-y, 86:10, (1085-1095), Online publication date: 1-Oct-2008. Dorn G (2007) The Fuzzy Logic of Physiological Cardiac Hypertrophy, Hypertension, 49:5, (962-970), Online publication date: 1-May-2007. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai H, Kim I, Tuteja D, Mateo R, Singapuri A, Davis B, Low R, Hammock B and Chiamvimonvat N (2006) Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors, Proceedings of the National Academy of Sciences, 10.1073/pnas.0609158103, 103:49, (18733-18738), Online publication date: 5-Dec-2006. Okere I, Young M, McElfresh T, Chess D, Sharov V, Sabbah H, Hoit B, Ernsberger P, Chandler M and Stanley W (2006) Low Carbohydrate/High-Fat Diet Attenuates Cardiac Hypertrophy, Remodeling, and Altered Gene Expression in Hypertension, Hypertension, 48:6, (1116-1123), Online publication date: 1-Dec-2006.Lu H, Fedak P, Dai X, Du C, Zhou Y, Henkelman M, Mongroo P, Lau A, Yamabi H, Hinek A, Husain M, Hannigan G and Coles J (2006) Integrin-Linked Kinase Expression Is Elevated in Human Cardiac Hypertrophy and Induces Hypertrophy in Transgenic Mice, Circulation, 114:21, (2271-2279), Online publication date: 21-Nov-2006. Strömer H, Palmieri E, De Groot M, Di Rella F, Leupold A, Horn M, Monti M, Napoli R, Di Gianni A, Isgaard J, Saccà L, Neubauer S and Cittadini A (2006) Growth hormone- and pressure overload-induced cardiac hypertrophy evoke different responses to ischemia-reperfusion and mechanical stretch, Growth Hormone & IGF Research, 10.1016/j.ghir.2005.09.002, 16:1, (29-40), Online publication date: 1-Feb-2006. Colan S (2007) Ventricular Function in Pressure Overload Lesions Ventricular Function and Blood Flow in Congenital Heart Disease, 10.1002/9780470994849.ch11, (185-204) Dorn G and Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy, Journal of Clinical Investigation, 10.1172/JCI24178, 115:3, (527-537), Online publication date: 1-Mar-2005. Booz G (2005) Putting the Brakes on Cardiac Hypertrophy, Hypertension, 45:3, (341-346), Online publication date: 1-Mar-2005. Arya R, Kedar V, Hwang J, McDonough H, Li H, Taylor J and Patterson C (2004) Muscle ring finger protein-1 inhibits PKCε activation and prevents cardiomyocyte hypertrophy, Journal of Cell Biology, 10.1083/jcb.200402033, 167:6, (1147-1159), Online publication date: 20-Dec-2004. Sano M and Schneider M (2004) Cyclin-Dependent Kinase-9, Circulation Research, 95:9, (867-876), Online publication date: 29-Oct-2004. LAMMERDING J, KAMM R and LEE R (2004) Mechanotransduction in Cardiac Myocytes, Annals of the New York Academy of Sciences, 10.1196/annals.1302.005, 1015:1, (53-70), Online publication date: 1-May-2004. van Rooij E, Doevendans P, Crijns H, Heeneman S, Lips D, van Bilsen M, Williams R, Olson E, Bassel-Duby R, Rothermel B and De Windt L (2004) MCIP1 Overexpression Suppresses Left Ventricular Remodeling and Sustains Cardiac Function After Myocardial Infarction, Circulation Research, 94:3, (e18-e26), Online publication date: 20-Feb-2004. Saupe K, Sobol S, Koh S and Apstein C (2003) Effects of AT1 Receptor Block Begun Late in Life on Normal Cardiac Aging in Rats, Journal of Cardiovascular Pharmacology, 10.1097/00005344-200310000-00017, 42:4, (573-580), Online publication date: 1-Oct-2003. Hamamori Y and Schneider M (2003) HATs off to Hop: recruitment of a class I histone deacetylase incriminates a novel transcriptional pathway that opposes cardiac hypertrophy, Journal of Clinical Investigation, 10.1172/JCI200319834, 112:6, (824-826), Online publication date: 15-Sep-2003. Dorn G, Robbins J and Sugden P (2003) Phenotyping Hypertrophy, Circulation Research, 92:11, (1171-1175), Online publication date: 13-Jun-2003. Sano M, Abdellatif M, Oh H, Xie M, Bagella L, Giordano A, Michael L, DeMayo F and Schneider M (2002) Activation and function of cyclin T–Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy, Nature Medicine, 10.1038/nm778, 8:11, (1310-1317), Online publication date: 1-Nov-2002. January 1, 2002Vol 105, Issue 1 Advertisement Article InformationMetrics https://doi.org/10.1161/circ.105.1.8PMID: 11772868 Originally publishedJanuary 1, 2002 Keywordshypertrophystresscardiac outputEditorialsPDF download Advertisement
Referência(s)